Top Page
Pharmaron Beijing Co., Ltd. Class H
(3759)
Pharmaron Beijing Co., Ltd. Class H (3759) vs. iShares MSCI Hong Kong ETF (EWH)
Pharmaron Beijing Co., Ltd. Class H Business Overview & Revenue Model
Pharmaron Beijing Co., Ltd. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.49B | 12.28B | 11.54B | 10.27B | 7.44B | 5.13B |
| Gross Profit | 4.61B | 4.20B | 4.12B | 3.77B | 2.68B | 1.92B |
| EBITDA | 2.22B | 3.38B | 2.95B | 2.53B | 2.49B | 1.72B |
| Net Income | 1.51B | 1.79B | 1.60B | 1.37B | 1.66B | 1.17B |
Balance Sheet | ||||||
| Total Assets | 25.80B | 23.93B | 26.48B | 20.49B | 18.39B | 11.91B |
| Cash, Cash Equivalents and Short-Term Investments | 2.28B | 2.81B | 6.72B | 2.24B | 5.10B | 3.85B |
| Total Debt | 6.39B | 5.54B | 9.36B | 6.12B | 5.29B | 1.05B |
| Total Liabilities | 10.62B | 9.70B | 13.24B | 9.65B | 8.09B | 2.98B |
| Stockholders Equity | 14.61B | 13.62B | 12.56B | 10.55B | 10.13B | 8.87B |
Cash Flow | ||||||
| Free Cash Flow | 812.99M | 536.02M | -111.78M | -807.04M | -34.78M | 332.77M |
| Operating Cash Flow | 3.27B | 2.58B | 2.75B | 2.14B | 2.06B | 1.65B |
| Investing Cash Flow | -3.90B | -2.02B | -2.25B | -2.21B | -5.26B | -3.37B |
| Financing Cash Flow | -237.76M | -4.80B | 3.92B | -1.42B | 3.66B | -280.18M |
Pharmaron Beijing Co., Ltd. Class H Technical Analysis
Pharmaron Beijing Co., Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | HK$55.94B | 22.32 | 10.94% | 1.04% | 14.50% | -19.24% | |
62 Neutral | HK$39.21B | 25.95 | 6.00% | 1.57% | 12.35% | 34.32% | |
60 Neutral | HK$27.95B | ― | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | HK$14.67B | -8.64 | -30.41% | ― | 23.87% | 30.08% | |
38 Underperform | HK$36.44B | -20.84 | -15.06% | ― | 38.56% | 48.26% |
Pharmaron Beijing Co., Ltd. Class H Corporate Events
Pharmaron Beijing Co., Ltd. has completed a placing of 58,440,762 new H shares under its general issuance mandate, raising net proceeds of approximately HK$1.32 billion through placements to at least six independent investors at HK$22.82 per share. The funds will primarily be used to expand project development and increase capabilities and production capacity in laboratory services and drug process development and manufacturing facilities, with smaller portions allocated to debt repayment and working capital. Following the transaction, total issued share capital has risen to 1,829,372,987 shares, increasing the proportion of H shares from 16.62% to 19.28% and slightly diluting existing A-share and H-share holdings, thereby broadening the company’s international investor base and optimizing its capital structure.
The most recent analyst rating on (HK:3759) stock is a Hold with a HK$24.00 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
Pharmaron Beijing Co., Ltd. has entered into a placing agreement with Goldman Sachs (Asia) L.L.C. and The Hongkong and Shanghai Banking Corporation Limited to issue 58,440,762 new H shares at HK$22.82 per share under its existing general issuance mandate. The new shares represent about 19.86% of its existing H-share capital and 3.30% of total issued shares, and will be allocated to at least six independent professional, institutional and other investors, with listing approval to be sought from the Hong Kong Stock Exchange; while the transaction is not subject to further shareholder approval, completion remains conditional and may not proceed, prompting the company to urge shareholders and investors to exercise caution.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$26.00 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
Pharmaron Beijing Co., Ltd. has issued an estimate for its 2025 annual results, projecting revenue between RMB 13.87 billion and RMB 14.24 billion, representing a year-on-year increase of 13% to 16%. Despite this top-line growth and an expected 36% to 41% rise in net profit attributable to owners of the parent excluding non-recurring items, as well as a 10% to 15% increase in non-IFRS adjusted net profit, the company anticipates a 6% to 10% decline in reported net profit attributable to owners of the parent due to non-recurring gains or losses and other adjustments. The guidance highlights solid underlying operational momentum and improved core profitability, while signaling that headline net profit will be pressured by non-recurring factors, a distinction that is likely to be closely watched by investors assessing the company’s earnings quality and growth trajectory in the competitive pharmaceutical services sector.
The most recent analyst rating on (HK:3759) stock is a Hold with a HK$21.00 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
Pharmaron Beijing Co., Ltd. announced that it successfully held its first extraordinary general meeting of 2025 in Beijing, with shareholders representing approximately 48.6% of voting share capital participating either in person or by proxy. All proposed ordinary resolutions were passed by a large majority, including the by‑election of an independent non‑executive director for the third session of the board and a series of amendments to key corporate governance and risk‑management policies, covering related‑party and connected transactions, external guarantees, external investments, independent non‑executive directors’ working procedures, use of proceeds, cumulative voting rules, and director nomination procedures. The strong approval rates underscore broad shareholder support for the company’s governance framework, which may strengthen regulatory compliance, enhance oversight of capital use and transactions, and reinforce the board’s independence, with potential implications for investor confidence and the company’s long‑term governance standards.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
Pharmaron Beijing Co., Ltd. has appointed its chief financial officer and board secretary, Mr. Li Shing Chung Gilbert, as the employee representative director for the third session of its board, following his election at an employee representatives’ meeting held on 18 December 2025 in line with PRC company law and the company’s articles of association. Mr. Li, a long-serving finance executive with extensive experience in accounting, corporate finance, and M&A, will not receive separate remuneration for this board role and holds an indirect minority stake in the company through Pharmaron Holdings Limited, a move that further integrates employee representation into the boardroom without altering the existing shareholder approval process or control structure.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
Pharmaron Beijing Co., Ltd. has announced the current composition of its board of directors, which includes executive, non-executive, independent non-executive and employee representative directors, led by chairman Dr. Lou Boliang. The company has also detailed the structure of its four key board committees—Audit, Remuneration and Appraisal, Nomination, and Strategy—clarifying chairperson and member roles among directors, a move that underscores its corporate governance framework and may provide investors and other stakeholders with greater transparency into oversight and strategic decision-making.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
Pharmaron Beijing Co., Ltd. has announced its first extraordinary general meeting of 2025, scheduled for December 18, 2025. The meeting will address several resolutions including the by-election of an independent non-executive director and amendments to various management policies and articles of association. These changes are aimed at enhancing corporate governance and operational efficiency, potentially impacting the company’s strategic direction and stakeholder engagement.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
Pharmaron Beijing Co., Ltd. announced a supplemental update regarding its acquisition of an 82.54% interest in Biortus, a move that constitutes a connected transaction. The company conducted a comprehensive valuation of Biortus by comparing it with four other listed companies in the same industry, focusing on profitability as a key indicator. This acquisition is expected to strengthen Pharmaron’s position in the CRO market, leveraging Biortus’ steady growth in revenue and profits.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
Pharmaron Beijing Co., Ltd. has established an Audit Committee under its Board of Directors to enhance corporate governance and ensure effective oversight of senior management. The committee, composed of independent non-executive directors, will oversee the company’s financial disclosures and audit processes, thereby strengthening decision-making and internal controls.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
Pharmaron Beijing Co., Ltd. has established a Remuneration and Appraisal Committee to enhance its governance structure by formulating appraisal standards and remuneration policies for its directors and senior management. This initiative aims to optimize corporate governance and ensure accountability within the company’s leadership, potentially strengthening its industry position and stakeholder trust.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
Pharmaron Beijing Co., Ltd. has established a Nomination Committee to enhance its corporate governance by regulating the appointment of directors and senior management. The committee, composed of five directors with a majority being independent non-executive directors, is tasked with researching selection criteria and advising on candidates, aiming to optimize the board’s composition and improve governance structure.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
Pharmaron Beijing Co., Ltd. has announced its acquisition of an 82.54% equity interest in Biortus for approximately RMB1,346 million. This acquisition, structured as a connected transaction under the Hong Kong Listing Rules, will position Biortus as a subsidiary of Pharmaron, potentially enhancing its market presence and operational capabilities. The transaction involves several connected parties and is subject to certain conditions precedent, highlighting its strategic importance and potential impact on Pharmaron’s growth trajectory.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
Pharmaron Beijing Co., Ltd. has announced the resignation of Mr. Tsang Kwan Hung Benson from his role as an independent non-executive director due to the nearing completion of his six-year term. The company has nominated Prof. Tsang King Fung as a candidate for the position, pending approval at the upcoming extraordinary general meeting. This change in leadership is part of the company’s ongoing efforts to maintain compliance and ensure robust governance, which could impact its strategic direction and reassure stakeholders of its commitment to regulatory standards.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.